Cancer Pathogenesis and DNA Sensing

Biological DNA Sensor: The Impact of Nucleic Acids on Diseases and Vaccinology

Volumn , Issue , 2013, Pages 205-229

  Shen, Y J ^a,b   Lam, A R ^a,b   Ho, S W S ^a   Koo, C X ^a,b,c   Le Bert, N ^a   Gasser, S ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Cancer; DNA damage response; DNA sensor; Inflammasome; Innate immunity

Indexed keywords

EID: 84904029358     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-404732-7.00009-5     Document Type: Chapter

References (234)

1. Halazonetis TD, Gorgoulis VG, Bartek J An Oncogene-induced DNA damage model for cancer development. Science 2008, 319(5868):1352-1355.
2. Gasser S, Raulet DH The DNA damage response, immunity and cancer. Semin Cancer Biol 2006, 16(5):344-347.
3. Medzhitov R TLR-mediated innate immune recognition. Semin Immunol 2007, 19(1):1-2.
4. Akira S, Takeda K Toll-like receptor signalling. Nat Rev Immunol 2004, 4(7):499-511.
5. Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+T cell responses through CD8{alpha}+dendritic cells. J Exp Med 2011, 208(10):2005-2016.
6. Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005, 6(7):722-729.
7. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208(10):1989-2003.
8. Raulet DH, Guerra N Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009, 9(8):568-580.
9. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448(7152):501-505.
10. Rebsamen M, Heinz LX, Meylan E, Michallet M-CEC, Schroder K, Hofmann K, et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep 2009, 10(8):916-922.
11. Schwartz T, Behlke J, Lowenhaupst K, Heinemann U, Rich A Structure of the DLM-1-Z-DNA complex reveals a conserved family of Z-DNA-binding proteins. Nat Struct Biol 2001, 8(9):761-765.
12. Deigendesch N, Koch-Nolte F, Rothenburg S ZBP1 subcellular localization and association with stress granules is controlled by its Z-DNA binding domains. Nucleic Acids Res 2006, 34(18):5007-5020.
13. Buchan JR, Parker R Eukaryotic stress granules: the ins and outs of translation. Mol Cell 2009, 36(6):932-941.
14. White JP, Lloyd RE Regulation of stress granules in virus systems. Trends Microbiol 2012, 20(4):175-183.
15. Fu Y, Comella N, Tognazzi K, Brown LF, Dvorak HF, Kocher O Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. Gene 1999, 240(1):157-163.
16. Wang G, Christensen LA, Vasquez KM Z-DNA-forming sequences generate large-scale deletions in mammalian cells. Proc Natl Acad Sci USA 2006, 103(8):2677-2682.
17. Gariglio M, Mondini M, De Andrea M, Landolfo S The multifaceted interferon-inducible p200 family proteins: from cell biology to human pathology. J Interferon Cytokine Res 2011, 31(1):159-172.
18. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458(7237):514-518.
19. Fernandes-Alnemri T, Yu J-W, Datta P, Wu J, Alnemri ES AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458(7237):509-513.
20. Bürckstümmer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009, 10(3):266-272.
21. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010, 11(11):997-1004.
22. Kerur N, Veettil MV, Sharma-Walia N, Bottero V, Sadagopan S, Otageri P, et al. IFI16 Acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi sarcoma-associated herpesvirus infection. Cell Host Microbe 2011, 9(5):363-375.
23. Johnstone RW, Trapani JA Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol 1999, 19(9):5833-5838.
24. Asefa B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA, Keller JR The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation. Blood Cells Mol Dis 2004, 32(1):155-167.
25. Cresswell KS, Clarke CJP, Jackson JT, Darcy PK, Trapani JA, Johnstone RW Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. Biochem Biophys Res Commun 2005, 326(2):417-424.
26. Trapani JA, Browne KA, Dawson MJ, Ramsay RG, Eddy RL, Show TB, et al. A novel gene constitutively expressed in human lymphoid cells is inducible with interferon-gamma in myeloid cells. Immunogenetics 1992, 36(6):369-376.
27. Wei W, Clarke CJP, Somers GR, Cresswell KS, Loveland KA, Trapani JA, et al. Expression of IFI 16 in epithelial cells and lymphoid tissues. Histochem Cell Biol 2003, 119(1):45-54.
28. Luan Y, Lengyel P, Liu C-J p204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation. Cytokine Growth Factor Rev 2008, 19(5-6):357-369.
29. Choubey D, Lengyel P Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. J Biol Chem 1995, 270(11):6134-6140.
30. Ding B, Lengyel P p204 protein is a novel modulator of Ras activity. J Biol Chem 2008, 283(9):5831-5848.
31. Duan X, Ponomareva L, Veeranki S, Panchanathan R, Dickerson E, Choubey D Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res 2011, 9(5):589-602.
32. Song LL, Alimirah F, Panchanathan R, Xin H, Choubey D Expression of an IFN-inducible cellular senescence gene, IFI16, is up-regulated by p53. Mol Cancer Res 2008 Nov, 6(11):1732-1741.
33. Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P, et al. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res 2004, 293(2):331-345.
34. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444(7119):638-642.
35. Johnstone RW, Wei W, Greenway A, Trapani JA Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 2000, 19(52):6033-6042.
36. Fujiuchi N Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem 2004, 279(19):20339-20344.
37. Gugliesi F Up-regulation of the interferon-inducible IFI16 gene by oxidative stress triggers p53 transcriptional activity in endothelial cells. J Leukocyte Biol 2005, 77(5):820-829.
38. Aglipay JA, Lee SW, Okada S, Fujiuchi N, Ohtsuka T, Kwak JC, et al. A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. Oncogene 2003, 22(55):8931-8938.
39. Azzimonti B, Pagano M, Mondini M, De Andrea M, Valente G, Monga G, et al. Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous cell carcinoma: immunohistochemical study including correlation with retinoblastoma protein, human papillomavirus infection and proliferation index. Histopathology 2004, 45(6):560-572.
40. De Andrea M, Gioia D, Mondini M, Azzimonti B, Renò F, Pecorari G, et al. Effects of IFI16 overexpression on the growth and doxorubicin sensitivity of head and neck squamous cell carcinoma-derived cell lines. Head Neck 2007, 29(9):835-844.
41. Alimirah F, Chen J, Davis FJ, Choubey D IFI16 in human prostate cancer. Mol Cancer Res 2007, 5(3):251-259.
42. Liu C, Ding B, Wang H, Lengyel P The MyoD-inducible p204 protein overcomes the inhibition of myoblast differentiation by Id proteins. Mol Cell Biol 2002, 22(9):2893-2905.
43. Lengyel P, Liu CJ The p200 family protein p204 as a modulator of cell proliferation and differentiation: a brief survey. Cell Mol Life Sci 2009, 67(3):335-340.
44. Dawson MJ, Trapani JA IFI 16 gene encodes a nuclear protein whose expression is induced by interferons in human myeloid leukaemia cell lines. J Cell Biochem 2004, 57(1):39-51.
45. Choubey D, Walter S, Geng Y, Xin H Cytoplasmic localization of the interferon-inducible protein that is encoded by the AIM2 (absent in melanoma) gene from the 200-gene family. FEBS Lett 2000, 474(1):38-42.
46. Roberts T, Idris A, Dunn J, Kelly G, Burnton C, Hodgson S, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009, 323(5917):1057-1060.
47. Li B p202, an interferon-inducible modulator of transcription, inhibits transcriptional activation by the p53 tumor suppressor protein, and a segment from the p53-binding protein 1 that binds to p202 overcomes this inhibition. J Biol Chem 1996, 271(44):27544-27555.
48. Abdelhaleem M Do human RNA helicases have a role in cancer?. Biochim Biophys Acta 2004, 1704(1):37-46.
49. Linder P Dead-box proteins: a family affair-active and passive players in RNP-remodeling. Nucleic Acids Res 2006, 34(15):4168-4180.
50. Desmet CJ, Ishii KJ Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012, 12(7):479-491.
51. Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, et al. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011, 34(6):866-878.
52. Kim T, Pazhoor S, Bao M, Zhang Z, Hanabuchi S, Facchinetti V, et al. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2010, 107(34):15181-15186.
53. Abdelhaleem M, Maltais L, Wain H The human DDX and DHX gene families of putative RNA helicases. Genomics 2003, 81(6):618-622.
54. Reddy TR, Tang H, Xu W, Wong-Staal F Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA. Oncogene 2000, 19(32):3570-3575.
55. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nature Genet 1998, 19(3):254-256.
56. Ohno M, Shimura Y A human RNA helicase-like protein, HRH1, facilitates nuclear export of spliced mRNA by releasing the RNA from the spliceosome. Genes Dev 1996, 10(8):997-1007.
57. Li J, Tang H, Mullen TM, Westberg C, Reddy TR, Rose DW, et al. A role for RNA helicase A in post-transcriptional regulation of HIV type 1. Proc Natl Acad Sci USA 1999, 96(2):709-714.
58. Zhang S, Herrmann C, Grosse F Pre-mRNA and mRNA binding of human nuclear DNA helicase II (RNA helicase A). J Cell Sci 1999, 112(Pt 7):1055-1064.
59. Tang H, Gaietta GM, Fischer WH, Ellisman MH, Wong-Staal F A cellular cofactor for the constitutive transport element of type D retrovirus. Science 1997, 276(5317):1412-1415.
60. Tang H, Wong-Staal F Specific interaction between RNA helicase A and Tap, two cellular proteins that bind to the constitutive transport element of type D retrovirus. J Biol Chem 2000, 275(42):32694-32700.
61. Yedavalli VSRK, Neuveut C, Chi Y-H, Kleiman L, Jeang K-T Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 2004, 119(3):381-392.
62. Tang H, McDonald D, Middlesworth T, Hope TJ, Wong-Staal F The carboxyl terminus of RNA helicase A contains a bidirectional nuclear transport domain. Mol Cell Biol 1999, 19(5):3540-3550.
63. Fujii R, Okamoto M, Aratani S, Oishi T, Ohshima T, Taira K, et al. A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1. J Biol Chem 2001, 276:5445-5451.
64. Jain A, Bacolla A, Chakraborty P, Grosse F, Vasquez KM Human DHX9 helicase unwinds triple-helical DNA structures. Biochemistry 2010, 49(33):6992-6999.
65. Chakraborty P, Grosse F WRN helicase unwinds Okazaki fragment-like hybrids in a reaction stimulated by the human DHX9 helicase. Nucleic Acids Res 2010, 38(14):4722-4730.
66. Wei X, Pacyna-Gengelbach M, Schlüns K, An Q, Gao Y, Cheng S, et al. Analysis of the RNA helicase A gene in human lung cancer. Oncol Rep 2004, 11(1):253-258.
67. Myöhänen S, Baylin SB Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter. J Biol Chem 2001, 276(2):1634-1642.
68. Aratani S, Fujii R, Fujita H, Fukamizu A, Nakajima T Aromatic residues are required for RNA helicase A mediated transactivation. Int J Mol Med 2003, 12(2):175-180.
69. Schlegel BP, Starita LM, Parvin JD Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells. Oncogene 2003, 22(7):983-991.
70. Tran H, Schilling M, Wirbelauer C, Hess D, Nagamine Y Facilitation of mRNA deadenylation and decay by the exosome-bound, DExH protein RHAU. Mol Cell 2004, 13(1):101-111.
71. Iwamoto F, Stadler M, Chalupníková K, Oakeley E, Nagamine Y Transcription-dependent nucleolar cap localization and possible nuclear function of DExH RNA helicase RHAU. Exp Cell Res 2008, 314(6):1378-1391.
72. Chalupníková K, Lattmann S, Selak N, Iwamoto F, Fujiki Y, Nagamine Y Recruitment of the RNA helicase RHAU to stress granules via a unique RNA-binding domain. J Biol Chem 2008, 283(50):35186-35198.
73. Vaughn JP, Creacy SD, Routh ED, Joyner-Butt C, Jenkins GS, Pauli S, et al. The DEXH protein product of the DHX36 gene is the major source of tetramolecular quadruplex G4-DNA resolving activity in HeLa cell lysates. J Biol Chem 2005, 280(46):38117-38120.
74. Lattmann S, Giri B, Vaughn JP, Akman SA, Nagamine Y Role of the amino terminal RHAU-specific motif in the recognition and resolution of guanine quadruplex-RNA by the DEAH-box RNA helicase RHAU. Nucleic Acids Res 2010, 38(18):6219-6233.
75. Maizels N Dynamic roles for G4 DNA in the biology of eukaryotic cells. Nature Struct Molec Biol 2006, 13(12):1055-1059.
76. Godbout R, Packer M, Katyal S, Bléoo S Cloning and expression analysis of the chicken DEAD box gene DDX1. Biochim Biophys Acta 2002, 1574(1):63-71.
77. Chen H-C, Lin W-C, Tsay Y-G, Lee S-C, Chang C-J An RNA helicase DDX1, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K. J Biol Chem 2002, 277(43):40403-40409.
78. Bléoo S, Sun X, Hendzel MJ, Rowe JM, Packer M, Godbout R Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3'-end processing of pre-MRNA. Mol Biol Cell 2001, 12(10):3046-3059.
79. Godbout R, Squire J Amplification of a DEAD box protein gene in retinoblastoma cell lines. Proc Natl Acad Sci USA 1993, 90(16):7578-7582.
80. Godbout R, Packer M, Bie W Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem 1998, 273(33):21161-21168.
81. Squire JA, Thorner PS, Weitzman S, Maggi JD, Dirks P, Doyle J, et al. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 1995, 10(7):1417-1422.
82. Fuller-Pace FV DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res 2006, 34(15):4206-4215.
83. Henning D Silencing of RNA helicase II/Gu inhibits mammalian ribosomal RNA production. J Biol Chem 2003, 278(52):52307-52314.
84. Yang H, Henning D, Valdez BC Functional interaction between RNA helicase II/Gu(alpha) and ribosomal protein L4. FEBS J 2005, 272(15):3788-3802.
85. Yang H Down-regulation of RNA helicase II/Gu results in the depletion of 18 and 28 S rRNAs in Xenopus oocyte. J Biol Chem 2003, 278(40):38847-38859.
86. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu Y-J The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 2011, 12(10):1-8.
87. Irion U, Leptin M, Siller K, Fuerstenberg S, Cai Y, Doe CQ, et al. Abstrakt, a DEAD box protein, regulates Insc levels and asymmetric division of neural and mesodermal progenitors. Curr Biol 2004, 14(2):138-144.
88. Irion U, Leptin M Developmental and cell biological functions of the Drosophila DEAD-box protein abstrakt. Curr Biol 1999, 9(23):1373-1381.
89. Schmucker D, Vorbrüggen G, Yeghiayan P, Fan HQ, Jäckle H, Gaul U The Drosophila gene abstrakt, required for visual system development, encodes a putative RNA helicase of the DEAD box protein family. Mech Dev 2000, 91(1-2):189-196.
90. Reed AL, Yamazaki H, Kaufman JD, Rubinstein Y, Murphy B, Johnson AC Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor. J Biol Chem 1998, 273(34):21594-21602.
91. Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a [beta]-catenin-dependent pathway. Nat Immunol 2010, 11(6):487-494.
92. Clevers H Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480.
93. Kypta RM, Waxman J Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol 2012, 9:418-428.
94. Städeli R, Hoffmans R, Basler K Transcription under the control of nuclear arm/β-catenin. Current Biol 2006, 16(10):R378-R385.
95. Michaelson JS, Leder P Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 2001, 20(37):5093-5099.
96. Ohtsuka H, Oikawa M, Ariake K, Rikiyama T, Motoi F, Katayose Y, et al. GC-binding factor 2 interacts with dishevelled and regulates Wnt signaling pathways in human carcinoma cell lines. Int J Cancer 2011, 129(7):1599-1610.
97. Suriano AR, Sanford AN, Kim N, Oh M, Kennedy S, Henderson MJ, et al. GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol Cell Biol 2005, 25(20):9073-9081.
98. Shibutani M, Lazarovici P, Johnson AC, Katagiri Y, Guroff G Transcriptional down-regulation of epidermal growth factor receptors by nerve growth factor treatment of PC12 cells. J Biol Chem 1998, 273(12):6878-6884.
99. Rikiyama T, Curtis J, Oikawa M, Zimonjic DB, Popescu N, Murphy BA, et al. GCF2: expression and molecular analysis of repression. Biochim Biophys Acta 2003, 1629(1-3):15-25.
100. Ariake K, Ohtsuka H, Motoi F, Douchi D, Oikawa M, Rikiyama T, et al. GCF2/LRRFIP1 promotes colorectal cancer metastasis and liver invasion through integrin-dependent RhoA activation. Cancer Lett 2012, 325(1):99-107.
101. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.
102. Li Y, Li W, Yang Y, Lu Y, He C, Hu G, et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009, 1286:13-18.
103. Shen D-W, Pouliot LM, Gillet J-P, Ma W, Johnson AC, Hall MD, et al. The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Mol Pharm 2012, 9(6):1822-1833.
104. Liu F, Gu J Retinoic acid inducible gene-I, more than a virus sensor. Protein Cell 2011, 2(5):351-357.
105. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314(5801):994-997.
106. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010, 140(3):397-408.
107. Chiu Y-H, MacMillan JB, Chen ZJ RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009, 138(3):576-591.
108. Su Z-Z, Sarkar D, Emdad L, Barral PM, Fisher PB Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J Cell Physiol 2007, 213(2):502-510.
109. Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009, 119(8):2399-2411.
110. Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000, 96(4):1496-1504.
111. Tsai F-M, Shyu R-Y, Jiang S-Y RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cell Signal 2006, 18(3):349-358.
112. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388.
113. Lange SS, Vasquez KM HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog 2009, 48(7):571-580.
114. van Beijnum JR, Petersen K, Griffioen AW Tumor endothelium is characterized by a matrix remodeling signature. Front Biosci (Schol Ed) 2009, 1:216-225.
115. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009, 7:17.
116. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13(10):2836-2848.
117. Brezniceanu M-L, Völp K, Bösser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003, 17(10):1295-1297.
118. Chung HW, Lee S-G, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009, 7:38.
119. Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005, 166(4):1259-1263.
120. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405(6784):354-360.
121. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13(9):1050-1059.
122. Morio T, Kim H Ku, Artemis, and ataxia-telangiectasia-mutated: signalling networks in DNA damage. Int J Biochem Cell Biol 2008, 40(4):598-603.
123. Rossi ML, Ghosh AK, Bohr VA Roles of Werner syndrome protein in protection of genome integrity. DNA Repair 2010, 9(3):331-344.
124. Zhang X, Brann TW, Zhou M, Yang J, Oguariri RM, Lidie KB, et al. Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J Immunol 2011, 186:4541-4545.
125. Takaoka A, Taniguchi T Cytosolic DNA recognition for triggering innate immune responses. Adv Drug Deliv Rev 2008, 60(7):847-857.
126. Ishikawa H, Barber GN The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci 2010, 68(7):1157-1165.
127. Ishikawa H, Barber GN STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455(7213):674-678.
128. Heider MR, Munson M Exorcising the exocyst complex. Traffic 2012, 13(7):898-907.
129. Ishikawa H, Ma Z, Barber GN STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461(7265):788-792.
130. Camonis JH, White MA Ral GTPases: corrupting the exocyst in cancer cells. Trends Cell Biol 2005, 15(6):327-332.
131. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita J-B, Daviet L, Camonis J, et al. The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol 2008, 181(6):985-998.
132. Moskalenko S, Henry DO, Rosse C, Mirey G, Camonis JH, White MA The exocyst is a Ral effector complex. Nat Cell Biol 2001, 4(1):66-72.
133. Jin L, Waterman PM, Jonscher KR, Short CM, Reisdorph NA, Cambier JC MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol 2008, 28(16):5014-5026.
134. Jin L, Lenz LL, Cambier JC Cellular reactive oxygen species inhibit MPYS induction of IFNβ. PLoS ONE 2010, 5(12):e15142.
135. Heiber JF, Barber GN Evaluation of innate immune signaling pathways in transformed cells. Methods Mol Biol 2012, 797:217-238.
136. Kawai T, Akira S The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11(5):373-384.
137. Salaun B, Coste I, Rissoan M-C, Lebecque SJ, Renno T TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006, 176(8):4894-4901.
138. Han K-J, Su X, Xu L-G, Bin L-H, Zhang J, Shu H-B Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem 2004, 279(15):15652-15661.
139. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Häcker G Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 2010, 17(6):942-951.
140. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011, 43(3):449-463.
141. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003, 4(5):491-496.
142. Shen RR, Hahn WC Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011, 30(6):631-641.
143. Ou Y-H, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011, 41(4):458-470.
144. Chien Y, Kim S, Bumeister R, Loo Y-M, Kwon SW, Johnson CL, et al. RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006, 127(1):157-170.
145. Clément J-F, Meloche S, Servant MJ The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 2008, 18(9):889-899.
146. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 461(7269):108-112.
147. Chien Y, White MA Characterization of RalB-Sec5-TBK1 function in human oncogenesis. Meth Enzymol 2008, 438:321-329.
148. Qin B, Cheng K Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res 2010, 12(5):R74.
149. Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, et al. IKK-ε coordinates invasion and metastasis of ovarian cancer. Cancer Res 2012, 72(21):5494-5504.
150. Péant B, Forest V, Trudeau V, Latour M, Mes-Masson A-M, Saad F IκB-kinase-ε (IKKε/IKKi/IκBKε) expression and localization in prostate cancer tissues. Prostate 2011, 71(10):1131-1138.
151. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623-655.
152. Falvo JV, Parekh BS, Lin CH, Fraenkel E, Maniatis T Assembly of a functional beta interferon enhanceosome is dependent on ATF-2-c-jun heterodimer orientation. Mol Cell Biol 2000, 20(13):4814-4825.
153. Merika M, Williams AJ, Chen G, Collins T, Thanos D Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol Cell 1998, 1(2):277-287.
154. Barber GN Cytoplasmic DNA innate immune pathways. Immunol Rev 2011, 243(1):99-108.
155. Civas A, Génin P, Morin P, Lin R, Hiscott J Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKKepsilon. J Biol Chem 2006, 281(8):4856-4866.
156. Sakaguchi S, Negishi H, Asagiri M, Nakajima C, Mizutani T, Takaoka A, et al. Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock. Biochem Biophys Res Commun 2003, 306(4):860-866.
157. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000, 13(4):539-548.
158. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434(7034):772-777.
159. Honda K, Yanai H, Takaoka A, Taniguchi T Regulation of the type I IFN induction: a current view. Internat Immunol 2005, 17(11):1367-1378.
160. Kim T-K, Lee J-S, Oh S-Y, Jin X, Choi Y-J, Lee T-H, et al. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res 2007, 67(23):11133-11140.
161. Kim TY, Lee K-H, Chang S, Chung C, Lee H-W, Yim J, et al. Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3. J Biol Chem 2003, 278(17):15272-15278.
162. Roberts ZJ, Goutagny N, Perera P-Y, Kato H, Kumar H, Kawai T, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 2007, 204(7):1559-1569.
163. Tokunaga T, Naruke Y, Shigematsu S, Kohno T, Yasui K, Ma Y, et al. Aberrant expression of interferon regulatory factor 3 in human lung cancer. Biochem Biophys Res Commun 2010, 397(2):202-207.
164. Korherr C, Gille H, Schäfer R, Koenig-Hoffmann K, Dixelius J, Egland KA, et al. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 2006, 103(11):4240-4245.
165. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012, 18(8):1224-1234.
166. Romieu-Mourez R, Solis M, Nardin A, Goubau D, Baron-Bodo V, Lin R, et al. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res 2006, 66(21):10576-10585.
167. Pahl HL Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18(49):6853.
168. Karin M, Greten FR NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5(10):749-759.
169. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463(7283):899-905.
170. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100(12):2952-2960.
171. Grivennikov SI, Greten FR, Karin M Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
172. Luo J-L, Maeda S, Hsu L-C, Yagita H, Karin M Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004, 6(3):297-305.
173. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999, 5(7):828-831.
174. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 2004, 23(10):1902-1910.
175. Gilbert LA, Hemann MT Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev 2012, 26(15):1758-1768.
176. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15(2):103-113.
177. Bollrath J, Phesse TJ, Burstin von VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15(2):91-102.
178. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317(5834):121-124.
179. Wong VW-S, Yu J, Cheng AS-L, Wong GL-H, Chan H-Y, Chu ES-H, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009, 124(12):2766-2770.
180. Dunn GP, Koebel CM, Schreiber RD Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6(11):836-848.
181. Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998, 91(1):22-29.
182. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424(6948):516-523.
183. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36(3):401-414.
184. DeYoung KL, Ray ME, Su YA, Anzick SL, Johnstone RW, Trapani JA, et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 1997, 15(4):453-457.
185. Vilaysane A, Muruve DA The innate immune response to DNA. Sem Immunol 2009, 21(4):208-214.
186. Hornung V, Latz E Intracellular DNA recognition. Nat Rev Immunol 2010, 10(2):123-130.
187. Takeshita F, Ishii KJ Intracellular DNA sensors in immunity. Curr Opin Immunol 2008, 20(4):383-388.
188. Davis BK, Wen H, Ting JP-Y The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011, 29:707-735.
189. Landolfo S, Gariglio M, Gribaudo G, Lembo D The Ifi 200 genes: an emerging family of IFN-inducible genes. Biochimie 1998, 80(8):721-728.
190. Jin T, Perry A, Jiang J, Smith P, Curry JA, Unterholzner L, et al. Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity 2012, 36(4):561-571.
191. Ray ME, Su YA, Meltzer PS, Trent JM Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma. Oncogene 1996, 12(12):2527-2533.
192. Michel S, Kloor M, Singh S, Gdynia G, Roth W, Knebel Doeberitz von M, et al. Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation. Mol Carcinog 2010, 49(2):175-182.
193. Woerner SM, Kloor M, Mueller A, Rueschoff J, Friedrichs N, Buettner R, et al. Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene 2005, 24(15):2525-2535.
194. Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, et al. Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes. Oncogene 2003, 22(15):2226-2235.
195. Woerner SM, Kloor M, Schwitalle Y, Youmans H, Doeberitz MK, Gebert J, et al. The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer 2007, 46(12):1080-1089.
196. Patsos G, Germann A, Gebert J, Dihlmann S Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 2010, 126(8):1838-1849.
197. Ding Y, Wang L, Su L-K, Frey JA, Shao R, Hunt KK, et al. Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer. Oncogene 2004, 23(26):4556-4566.
198. Asefa B, Dermott JM, Kaldis P, Stefanisko K, Garfinkel DJ, Keller JR p205, A potential tumor suppressor, inhibits cell proliferation via multiple pathways of cell cycle regulation. FEBS Letters 2006 Feb, 580(5):1205-1214.
199. Chen I-F AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Molec Cancer Therap 2006, 5(1):1-7.
200. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15(10):1170-1178.
201. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10(3):241-247.
202. Martinon F, Mayor A, Tschopp J The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
203. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti T-D IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol 2010, 185(8):4912-4920.
204. McConnell BB, Vertino PM TMS1/ASC: the cancer connection. Apoptosis 2004, 9(1):5-18.
205. Masumoto J ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chemi 1999, 274(48):33835-33838.
206. Ohtsuka T, Ryu H, Minamishima YA, Macip S, Sagara J, Nakayama KI, et al. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol 2004, 6(2):121-128.
207. Ohtsuka T, Liu X-F, Koga Y, Kitajima Y, Nakafusa Y, Ha C-W, et al. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer. Oncogene 2005, 25(12):1807-1811.
208. Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, et al. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int J Cancer 2003, 106(2):198-204.
209. Yokoyama T, Sagara J, Guan X, Masumoto J, Takeoka M, Komiyama Y, et al. Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer. Cancer Lett 2003, 202(1):101-108.
210. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000, 60(22):6236-6242.
211. Moriai R, Tsuji N, Kobayashi D, Yagihashi A, Namiki Y, Takahashi H, et al. A proapoptotic caspase recruitment domain protein gene, TMS1, is hypermethylated in human breast and gastric cancers. Anticancer Res 2002 Nov, 22(6C):4163-4168.
212. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 2004, 10:2000-2006.
213. Tamandani DMK, Sobti RC, Shekari M, Huria A CpG island methylation of TMS1/ASC and CASP8 genes in cervical cancer. European J Med Res 2009, 14(2):71.
214. Machida EO Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006, 66(12):6210-6218.
215. Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate 2006, 66(7):687-695.
216. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992, 356(6372):768-774.
217. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N Molecular cloning of the interleukin-1 beta converting enzyme. Science 1992, 256(5053):97-100.
218. Jee CD, Lee HS, Bae SI, Yang HK, Lee YM, Rho MS, et al. Loss of caspase-1 gene expression in human gastric carcinomas and cell lines. Int J Oncol 2005, 26(5):1265.
219. Winter RN, Kramer A, Borkowski A, Kyprianou N Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 2001, 61(3):1227-1232.
220. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B, van der Vlist M, Boekhout T, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat Immunol 2012, 13(3):246-254.
221. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007, 67(3):1062-1071.
222. Hagemann T, Balkwill F, Lawrence T Inflammation and cancer: a double-edged sword. Cancer Cell 2007, 12(4):300-301.
223. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14(5):408-419.
224. Zitvogel L, Kepp O, Galluzzi L, Kroemer G Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012, 13(4):343-351.
225. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, et al. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Molec Cancer Res 2011, 9(11):1537-1550.
226. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2010, 285(9):6477-6488.
227. Scherbarth S, Orr FW Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Res 1997, 57(18):4105-4110.
228. Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006 Feb 15, 12(4):1088-1096.
229. Weinreich DM, Elaraj DM, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, et al. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res 2003, 63(18):5957-5961.
230. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000, 97(2):734-739.
231. Salcedo M, Diehl A, Olsson-Alheim M, Sundbäck J, van Kaer L, Karre K, et al. Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I deficient mice. J Immunol 1997, 158(7):3174-3180.
232. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai R-M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010, 207(8):1625-1636.
233. Cao R, Farnebo J, Kurimoto M, Cao Y Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999, 13(15):2195-2202.
234. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998, 101(6):1441-1452.